A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis

The primary objective is: To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG) The secondary objectives of the study are: * To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on: * Clinician-assessed signs of myasthenia gravis (MG) and muscle strength * Daily functioning that is impacted by signs and symptoms in patients with symptomatic gMG (cemdisiran monotherapy only). * Proportion of patients with improvements in daily function that is impacted by signs and symptoms of MG * Proportion of patients that have improvements in clinician-assessed signs of MG and muscle strength * Health related quality of life * Proportion of patients with minimal MG symptoms * Patient- and clinician-reported signs and symptoms of MG * To evaluate the safety and tolerability of pozelimab + cemdisiran and cemdisiran monotherapy * To assess the concentration of total pozelimab in serum * To assess the concentrations of cemdisiran and its metabolites in plasma * To assess the immunogenicity of pozelimab * To assess the concentration of total C5 in plasma * To assess the immunogenicity of cemdisiran * To study the effect of pozelimab + cemdisiran and cemdisiran monotherapy on complement activation